Schedule 13G ownership disclosure
Design Therapeutics Inc
Common Stock · CUSIP: 25056L103
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Star Irrevocable Trust #1 dated April 22, 2019
Shares: 3,834,355.00 · Class: 6.9%
- Jason Howerton
Shares: 0.00 · Class: 0.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-003348
- Form type
- SCHEDULE 13G/A
- Filer
- Design Therapeutics, Inc.
- CIK
- CIK 1807120
- Filed
- Feb 07, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership